Sale!

KCNC1 Gene Epilepsy progressive myoclonic type 7 Genetic Test

4,400 د.إ

-21%

The KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to identify mutations in the KCNC1 gene that are associated with Progressive Myoclonic Epilepsy Type 7 (EPM7). This condition is a rare neurological disorder characterized by a combination of myoclonus (sudden, involuntary muscle jerks) and seizures, alongside other potential symptoms such as cognitive decline and ataxia. The test plays a crucial role in the accurate diagnosis and management of the disorder, allowing for targeted therapeutic strategies and genetic counseling for affected families.

Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and examining it for specific genetic alterations in the KCNC1 gene. These mutations disrupt the normal function of Kv3.1, a protein essential for the rapid firing of neurons, leading to the symptoms observed in EPM7.

The cost of the KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is 4400 AED. Given the complexity of genetic testing and the specialized analysis involved, this cost reflects the comprehensive approach taken by DNA Labs UAE to ensure accurate and reliable results. For patients and families facing the challenges of Progressive Myoclonic Epilepsy Type 7, this test offers a valuable resource for diagnosis and future planning.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

KCNC1 Gene Epilepsy progressive myoclonic type 7 Genetic Test

Test Details

The KCNC1 gene is associated with progressive myoclonic epilepsy type 7, which is a rare form of epilepsy characterized by muscle jerks, seizures, and neurological deterioration. The NGS genetic test is a diagnostic tool that analyzes the DNA sequence of the KCNC1 gene to identify any mutations or variations that may be causing the disease. This test can help confirm a diagnosis, identify carriers of the disease, and provide information about the risk of passing the condition on to future generations. It can also aid in developing personalized treatment plans for affected individuals.

Test Components

  • Price: 4400.0 AED

Sample Condition

Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery

3 to 4 Weeks

Method

NGS Technology

Test Type

Neurological Disorders

Doctor

Neurologist

Test Department

Genetics

Pre Test Information

Clinical History of Patient who is going for KCNC1 Gene Epilepsy, progressive myoclonic type 7 NGS Genetic DNA Test

A Genetic Counselling session to draw a pedigree chart of family members affected with KCNC1 Gene Epilepsy, progressive myoclonic type 7

Test Name KCNC1 Gene Epilepsy progressive myoclonic type 7 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for KCNC1 Gene Epilepsy, progressive myoclonic type 7 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with KCNC1 Gene Epilepsy, progressive myoclonic type 7
Test Details

The KCNC1 gene is associated with progressive myoclonic epilepsy type 7, which is a rare form of epilepsy characterized by muscle jerks, seizures, and neurological deterioration. The NGS genetic test is a diagnostic tool that analyzes the DNA sequence of the KCNC1 gene to identify any mutations or variations that may be causing the disease. This test can help confirm a diagnosis, identify carriers of the disease, and provide information about the risk of passing the condition on to future generations. It can also aid in developing personalized treatment plans for affected individuals.